- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00968786
Home Monitoring in the Management of Hypertension and Diabetes Mellitus
A Trial of the Use of Multiple Automated Measuring Devices in the Management of Patients With Hypertension and Type 2 Diabetes Mellitus
연구 개요
상세 설명
Background:
Approximately 40% of type 2 diabetes patients are also with hypertension. There are many risk factors in these patients, and so it's difficult to manage these patients. With the improvement of the accuracy of automated measuring devices, the patients can use these devices to monitor blood pressure, blood glucose, body weight, visceral fat and other indicators at home, and contribute their own participation in the management of there own diseases. The home monitoring may improve the management of this chronic disease, and may decrease the incidence of fatal disease such as stroke, myocardial infarction, heart failure, renal dysfunction and other serious diseases.
Large-scale research will carry out to prove that whether home monitoring is valuable for preventing the incidence of fatal disease such as stroke, myocardial infarction, heart failure, renal dysfunction. And in the first, it is necessary to conduct a small sample (n = 100), short observation time (six months) research, to monitor blood pressure, blood glucose, body weight and other indicators of intermediate target detection, to explore the feasibility to carry out such large-scale research.
Objective:
In hypertensive and type 2 diabetes patients, conducted an open randomized controlled trial to explore the patient's own use blood pressure monitors, blood glucose meter and pedometer at home, and use the body composition measurement instruments in clinic, is to be more effective control of blood pressure, blood glucose, body weight, and reduce the risk of patients with albuminuria.
Inclusion criteria:
- Regardless of whether they are currently receiving antihypertensive therapy, systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than90 mmHg.
- Whether or not use oral hypoglycemic agents or insulin injections, the fasting plasma is higher than 7.0 mmol/L, or postprandial blood glucose higher than 11.1 mmol/L.
Exclusion criteria:
- with life-threatening disease.
- With the various effects of metabolic diseases such as hyperthyroidism, hypothyroidism, etc.
- stroke, myocardial infarction and other serious cardiovascular and cerebrovascular diseases occurred within 3 months.
- serum creatinine level hugher than 176.8 mol/L.
- Dementia or severe cognitive decline.
- unable to do a long-term follow-up study or do not agree to participate in this trial.
Sample estimates and statistical analysis:
In accordance with 6-month follow-up, the average difference between the two groups, systolic blood pressure 3 mmHg, glycated hemoglobin 0.2%, under the conditions of a= 0.05 and b= 0.10, the research needs of each group of about 50 patients, a total of 100.
Major findings of the statistics using t test comparing the two groups after 6 months follow-up observations from the baseline change in the margin, and calculated 95% confidence interval. At the same time will also use non-parametric Wilcoxon test were compared blood pressure, blood glucose and so many follow-up results of repeated measurements.
연구 유형
등록 (예상)
단계
- 해당 없음
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Regardless of whether they are currently receiving antihypertensive therapy, systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg.
- Whether or not use oral hypoglycemic agents or insulin injections, the fasting plasma is higher than 7.0 mmol/L, or postprandial blood glucose higher than 11.1 mmol/L.
Exclusion Criteria:
- With life-threatening disease.
- With the various effects of metabolic diseases such as hyperthyroidism, hypothyroidism, etc.
- Stroke, myocardial infarction and other serious cardiovascular and cerebrovascular diseases occurred within 3 months.
- Serum creatinine level higher than 176.8 mmol/L
- Dementia or severe cognitive decline
- Unable to do a long-term follow-up or do not agree to participate in this trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: no home monitoring
no automated measuring devices for patients use at home
|
automated measuring devices for patients using at home
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
blood pressure, blood glucose, body weight and visceral fat levels.
기간: 3,6 months
|
3,6 months
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
albuminuria
기간: 3 months, 6 months
|
3 months, 6 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Jiguang Wang, Doctor, Shanghai Jiao Tong University School of Medicine
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Home monitoring에 대한 임상 시험
-
Seoul National University HospitalSeoul National University모집하지 않고 적극적으로
-
University of North Carolina, Chapel HillNational Institute of Nursing Research (NINR)모병
-
Singapore General HospitalKK Women's and Children's Hospital; SingHealth Polyclinics완전한
-
Anita Misra-HebertPatient-Centered Outcomes Research Institute; The Cleveland Clinic모병
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)완전한
-
University Health Network, Toronto모병림프종 | 림프 증식 장애 | 유방암 1기 | 유방암 2기 | 대장암 2기 | 대장암 3기 | 유방암 3기 | 대장암 1기 | 두경부암 3기 | 유방암, 0기 | 두경부암 1기 | 두경부암 2기캐나다
-
Alberto Pilotto완전한